NASDAQ:TRVI Trevi Therapeutics (TRVI) Stock Price, News & Analysis $11.88 -0.23 (-1.90%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$11.89 +0.01 (+0.08%) As of 10/16/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Trevi Therapeutics Stock (NASDAQ:TRVI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Trevi Therapeutics alerts:Sign Up Key Stats Today's Range$11.70▼$12.0850-Day Range$11.88▼$18.8452-Week Range$9.82▼$20.22Volume2.72 million shsAverage Volume2.78 million shsMarket Capitalization$1.69 billionP/E RatioN/ADividend YieldN/APrice Target$27.08Consensus RatingModerate Buy Company Overview Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for conditions involving chronic cough and other debilitating symptoms for which available treatment options are limited. The company’s lead product candidate is Haduvio, an extended-release formulation of nalbuphine, an opioid receptor modulator being investigated as a potential treatment for chronic cough. Trevi is evaluating Haduvio for chronic cough associated with idiopathic pulmonary fibrosis (IPF), a progressive lung disease, as well as refractory chronic cough, which persists despite treatment of underlying conditions. The company has conducted clinical studies to assess the therapy’s ability to reduce cough frequency and severity and continues to advance its development through late-stage clinical programs. Haduvio is investigational and has not been approved for commercial use. Trevi Therapeutics was founded in 2011 and is headquartered in New Haven, Connecticut. The company’s activities are primarily focused on clinical development and regulatory advancement in the United States and other markets where it conducts clinical research. Trevi is led by President and Chief Executive Officer Jennifer Good.AI Generated. May Contain Errors. Read More Trevi Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreTRVI MarketRank™: 2.646123260435 of 5 starsTrevi Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 458th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingTrevi Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 11 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialTrevi Therapeutics has a consensus price target of $27.08, representing about 128.0% upside from its current price of $11.88.Amount of Analyst CoverageTrevi Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Trevi Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.48) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevi Therapeutics is -34.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevi Therapeutics is -34.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrevi Therapeutics has a P/B Ratio of 8.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Trevi Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.14% of the float of Trevi Therapeutics has been sold short.Short Interest Ratio / Days to CoverTrevi Therapeutics has a short interest ratio ("days to cover") of 8.33.Change versus previous monthShort interest in Trevi Therapeutics has recently increased by 21.28%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTrevi Therapeutics does not currently pay a dividend.Dividend GrowthTrevi Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.34 News SentimentTrevi Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Trevi Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows3 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Trevi Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $595,648.00 in company stock.Percentage Held by Insiders15.39% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Trevi Therapeutics' insider trading history. Receive TRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRVI Stock News HeadlinesDo Trevi Therapeutics’ (TRVI) CORAL Data and GSK’s Exit Reframe Its Chronic Cough Ambitions?October 14, 2026 | finance.yahoo.comTrevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual MeetingOctober 13, 2026 | globenewswire.comThis link won't stay freeThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightforward 3-step approach to trading same-day options, with entry, exit and max loss set before you ever place a trade. Plain English, no complicated math, done by market close. The price may return to 29.97 as soon as tomorrow.October 18 at 1:00 AM | Profits Run (Ad)Trevi Therapeutics' Sample Size Re-estimation for Chronic Cough Trial Likely Positive, Oppenheimer SaysSeptember 25, 2026 | marketscreener.comMMichael Thomas Heffernan Sells 39,473 Shares of Trevi Therapeutics (NASDAQ:TRVI) StockSeptember 18, 2026 | insidertrades.comTrevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comRaymond James Sticks to Its Buy Rating for Trevi Therapeutics (TRVI)September 5, 2026 | theglobeandmail.comTrevi Therapeutics (TRVI) Receives a New Rating from B. Riley SecuritiesSeptember 5, 2026 | theglobeandmail.comSee More Headlines TRVI Stock Analysis - Frequently Asked Questions How have TRVI shares performed this year? Trevi Therapeutics' stock was trading at $12.52 at the beginning of 2026. Since then, TRVI stock has decreased by 5.1% and is now trading at $11.88. How were Trevi Therapeutics' earnings last quarter? Trevi Therapeutics, Inc. (NASDAQ:TRVI) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.00. Read the conference call transcript. When did Trevi Therapeutics IPO? Trevi Therapeutics (TRVI) raised $70 million in an IPO on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager. Who are Trevi Therapeutics' major shareholders? Top institutional investors of Trevi Therapeutics include Assenagon Asset Management S.A. (2.48%). Insiders that own company stock include David P Meeker, Thomas Sciascia, Jennifer L Good, Farrell Simon, Lisa Delfini and Michael Thomas Heffernan. View institutional ownership trends. How do I buy shares of Trevi Therapeutics? Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Trevi Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include NVIDIA (NVDA), Definium Therapeutics (DFTX), Intel (INTC), Micron Technology (MU), Palantir Technologies (PLTR), Solid Biosciences (SLDB) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/06/2026Today10/18/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 12 days, TRVI's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TRVI CIK1563880 Webwww.trevitherapeutics.com Phone(203) 304-2499FaxN/AEmployees34Year Founded2011Price Target and Rating Average Price Target for Trevi Therapeutics$27.08 High Price Target$40.00 Low Price Target$16.00 Potential Upside/Downside+128.0%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$42.76 million Net MarginsN/A Pretax MarginN/A Return on Equity-23.59% Return on Assets-22.64% Debt Debt-to-Equity RatioN/A Current Ratio37.28 Quick Ratio37.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book8.31Miscellaneous Outstanding Shares142,480,000Free Float120,549,000Market Cap$1.69 billion OptionableOptionable Beta0.98 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:TRVI) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredThis link won't stay freeThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
